EXEL·Exelixis Inc.
EXEL|Analyst Targets
EXEL|Insider Trading
EXEL|Fundamentals
EXEL|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $0.90 | - | - |
| Q3'25 | $0.67 | $0.78 | +16.2% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $662M | - | - |
| Q3'25 | - | $598M | - |
EXEL|Monthly Returns
Market Data
EXEL Stock Snapshot
- Market cap
- 14.57B
- P/E ratio
- 16.9
- Day range
- $57.50 – $59.27
- News sentiment
- 64/100 · Bullish
- Analyst target
- $54.40 (-6.6%)
- Consensus
- Hold · 28 analysts
Exelixis Inc. screens well technically, with price sitting near its 52-week high. Institutional coverage is thorough here, so shifts in analyst expectations show up in price quickly.
Behaviour On Record
What EXEL's own history says about today's numbers
- Realized volatility (21d)
- 27.1% 11th pct
- Below its peak
- -0.4%
- vs 200-day average
- +19.9%
- Up days (1y)
- 52%
Exelixis Inc. is currently running 27.1% annualised volatility over the last 21 sessions. Measured against EXEL's own 13 years of daily returns rather than a market-wide average, that is the 11th percentile — unusually subdued by its own history, against a typical reading of 43.1%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.
EXEL is at its running peak. Across 12 full years on file its median worst-drawdown-in-a-year was -34.6%, with the deepest at -84.4% in 2014 — so highs have historically been given back before they were extended.
Price sits +19.9% from its 200-day moving average. Against every other day in its history, that gap ranks at the 73rd percentile — a somewhat wider gap than its own norm. Over the past year EXEL closed higher on 52% of sessions, and it is currently 2 sessions into a rising streak.
On October specifically: over 13 years of records, EXEL finished the month higher 5 of 13 times, with a median return of -6.8% and an average of -3.5%. Its strongest month historically has been November at +7.3% on average, its weakest March at -4.1%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.
Overnight risk is measurable too: EXEL has opened more than 2% away from the prior close in 387 of 3,267 sessions (11.8% of the time), with the largest gaps running +40.7% and -27.1%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.
All figures computed from 3,268 daily closes between 2013-10-07 and 2026-10-05, split-adjusted, recomputed daily. Percentiles are against EXEL's own 13-year history, not a peer group or index.
Sector Rotation
Is money rotating into or out of EXEL's sector?
Exelixis Inc. sits in the Health Care sector, currently ranked 3rd of 12 GICS sectors by relative-strength rotation score (lagging). Within its narrower Biotechnology industry group, EXEL ranks 10th of 15 tracked industries, lagging.
- Sector rank
- #3 of 12
- Sector state
- Lagging
- Sector rotation score
- 64
- Industry rank
- #10 of 15
Analyst Rating Changes
Are analysts turning bullish or bearish on EXEL?
BMO Capital most recently initiated coverage on Exelixis Inc. to Market Perform on Aug 19, 2026 with a price target of $54. Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.
- Latest action
- BMO Capital — Market Perform
- 90-day upgrades
- 0
- 90-day downgrades
- 0
- Net rating momentum
- 0
Held by These ETFs
News Sentiment Analysis
Sentiment gathered from recent headlines
Recent News Coverage
Most recent articles, ranked by recency (click to expand).
Technical Analysis
Real-time indicators across multiple timeframes
| Manager | Trend | Shares Held | % of Co. | Position Value | Filed |
|---|---|---|---|---|---|
| Citadel Advisors LLC | • Hold | 223,724 | 0.09% | $12.17M | 2026-09-02 |